SBIR-STTR Award

The Contractor Shall Utilize Nanoparticles to Deliver the Mper-Based Immunogens to Elicit Bnabs Against the MPER of HIV-1 gp41 to Develop a Protective
Award last edited on: 6/19/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$300,000
Award Phase
1
Solicitation Topic Code
77
Principal Investigator
Chowda Venkataravappa

Company Information

NeoVaxSyn Inc

4140 Cochrane Parkway
Ames, IA 50014
   (515) 708-5831
   N/A
   N/A
Location: Single
Congr. District: 04
County: Story

Phase I

Contract Number: 75N93021C00026
Start Date: 7/1/2021    Completed: 6/30/2022
Phase I year
2021
Phase I Amount
$300,000
Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop, evaluate, and optimize nanoparticle-based platforms to elicit broadly neutralizing antibodies against the membrane proximal external region (MPER) of the HIV-1 gp41 protein.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----